DealsJun 23, 2026, 07:06 AM
Nuvectis Pharma Licenses 2 Clinical Compounds from Haisco for $20M Upfront
AI Summary
Nuvectis Pharma, Inc. has entered into a license agreement with Haisco Pharmaceutical Group Co., Ltd. for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200. This strategic deal involves an upfront payment of $20 million, potential initial development milestones of up to $20 million, and up to an additional $1.4 billion in contingent payments based on future development, regulatory, and commercial milestones, plus tiered royalties. The agreement significantly expands Nuvectis' pipeline into complement-mediated diseases and enhances its oncology portfolio with potentially best-in-class assets.
Key Highlights
- Nuvectis Pharma entered an exclusive, royalty-bearing license agreement with Haisco Pharmaceutical Group.
- The agreement covers NXP100 (Complement Factor B inhibitor) and NXP200 (BRAF inhibitor) for ex-China rights.
- Nuvectis will pay Haisco an upfront payment of $20 million.
- Initial development milestone payments of up to $20 million may become payable.
- Haisco is eligible to receive up to an additional $1.4 billion in contingent payments.
- Tiered royalties will range from high-single digits to mid-teens based on net sales.
- NXP100 has composition of matter patents expiring in 2043, and NXP200 in 2042.
- The license agreement is subject to certain financing conditions Nuvectis must meet.
Price Impact
More from NVCT